Immune-mediated neuropathies represent a heterogeneous spectrum of peripheral nerve disorders that can be classified according to time course, predominant involvement of motor/sensory fibers, distribution of deficits and paraclinical parameters such as electrophysiology and serum antibodies. In the last few years, significant advances have been achieved in elucidating underlying pathomechanisms, which made it possible to identify potential therapeutic targets. In this review, we discuss the latest development in pathogenesis and treatment of immune-mediated neuropathies.
Allen, D., Lunn, M.P., Niermeijer, J. and Nobile-Orazio, E. (2007) Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst RevCD005376.
2.
Andersen, S.M., Ling, C.C., Zhang, P., Townson, K., Willison, H.J. and Bundle, D.R. (2004) Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barré syndrome. Org Biomol Chem2: 1199-1212.
3.
Asbury, A.K., Arnason, B.G. and Adams, R.D. (1969) The inflammatory lesion in idiopathic polyneuritis . Medicine4: 173-215.
4.
Auer, R., Bell, R. and Lee, M. (1989) Neuropathy with onion bulb formations and pure motor manifestations. Can J Neurol Sci16: 194-197.
5.
Axelson, H., Oberg, G. and Askmark, H. (2008a) No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy . Acta Neurol Scand117: 432-434.
6.
Axelson, H., Oberg, G. and Askmark, H. (2008b) Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP. J Neurol Neurosurg Psychiatry79: 612-614.
7.
Azulay, J., Blin, O., Pouget, J., Boucraut, J., Billé-Turc, F., Carles, G. and Serratrice, G. (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology44: 429-432.
8.
Bechtold, D.A., Yue, X., Evans, R.M., Davies, M., Gregson, N.A. and Smith, K.J. (2005) Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain128: 18-28.
9.
Benedetti, L., Briani, C., Franciotta, D., Carpo, M., Padua, L., Zara, G. et al. (2008) Long-term effect of rituximab in anti-mag polyneuropathy. Neurology71: 1742-1744.
10.
Benedetti, L., Briani, C., Grandis, M., Vigo, T., Gobbi, M., Ghiglione, E. et al. (2007) Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst12: 102-107.
11.
Brannagan, T.R., Pradhan, A., Heiman-Patterson, T., Winkelman, A., Styler, M., Topolsky, D. et al. (2002) High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology58: 1856-1858.
12.
Bril, V., Ilse, W.K., Pearce, R., Dhanani, A., Sutton, D. and Kong, K. (1996) Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain- Barré syndrome. Neurology46: 100-103.
13.
Buchwald, B., Ahangari, R. and Toyka, K.V. (2002) Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and alpha-latrotoxin in the absence of complement at the mouse neuromuscular junction. Neurosci Lett334: 25-28.
14.
Buchwald, B., Toyka, K.V., Zielasek, J., Weishaupt, A., Schweiger, S. and Dudel, J. (1998) Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study. Ann Neurol44: 913-922.
15.
Buchwald, B., Zhang, G., Vogt-Eisele, A.K., Zhang, W., Ahangari, R., Griffin, J.W. et al. (2007) Anti-ganglioside antibodies alter presynaptic release and calcium influx. Neurobiol Dis28: 113-121.
16.
Bullens, R.W., Halstead, S.K., O'Hanlon, G.M., Veitch, J., Molenaar, P.C., Willison, H.J. and Plomp, J.J. (2005) Concanavalin a inhibits pathophysiological effects of anti-ganglioside GQ1b antibodies at the mouse neuromuscular synapse. Muscle Nerve.
17.
Chan, Y., Allen, D., Fialho, D., Mills, K. and Hughes, R. (2006) Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry77: 114-116.
18.
Chaudhry, V., Corse, A., Cornblath, D., Kuncl, R., Drachman, D., Freimer, M., Miller, R. and Griffin, J. (1993) Multifocal motor neuropathy: response to human immune globulin. Ann Neurol33: 237-242.
19.
Chaudhry, V. and Swash, M. (2006) Multifocal motor neuropathy: is conduction block essential?. Neurology67: 558-559.
20.
Cheng, Q., Jiang, G.X., Fredrikson, S., Link, H. and De Pedro-Cuesta, J. (2000) Incidence of Guillain- Barré syndrome in Sweden 1996. Eur J Neurol7: 11-16.
21.
Chiò, A., Cocito, D., Bottacchi, E., Buffa, C., Leone, M., Plano, F. et al. (2007) Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry78: 1349-1353.
22.
Comi, G., Roveri, L., Swan, A., Willison, H., Bojar, M., Illa, I. et al. (2002) A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol249: 1370-1377.
23.
Créange, A., Chater, A., Brouet, J., Jaccard, A., Rahmouni, A., Lefaucheur, J. et al. (2008) A case of POEMS syndrome treated by autologous hematopoietic stem-cell transplantation. Nat Clin Pract Neurol4: 686-691.
24.
Dalakas, M. and Engel, W. (1980) Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol37: 637-640.
25.
Dalakas, M.C., Quarles, R.H., Farrer, R.G., Dambrosia, J., Soueidan, S., Stein, D.P. et al. (1996) A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol40: 792-795.
26.
Dalakas, M.C., Rakocevic, G., Salajegheh, M.K., Dambrosia, J., Hahn, A., Raju, R. et al. (2009) A double-blind, placebo-controlled study of rituximab in patients with anti-MAG antibody-demyelinating polyneuropathy . Ann Neurol, in press.
27.
Delmont, E., Azulay, J., Giorgi, R., Attarian, S., Verschueren, A., Uzenot, D. et al. (2006) Multifocal motor neuropathy with and without conduction block: a single entity?. Neurology67: 592-596.
28.
Diener, H.C., Haupt, W.F., Kloss, T.M., Rosenow, F., Philipp, T., Koeppen, S. et al. (2001) A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol46: 107-109.
29.
Dispenzieri, A., Kyle, R., Lacy, M., Rajkumar, S., Therneau, T., Larson, D. et al. (2003) POEMS syndrome: definitions and long-term outcome. Blood101: 2496-2506.
30.
Duggins, A., McLeod, J., Pollard, J., Davies, L., Yang, F., Thompson, E. et al. (1999) Spinal root and plexus hypertrophy in chronic inflammatory demyelinating polyneuropathy. Brain122: 1383-1390.
31.
Dyck, P., O'Brien, P., Oviatt, K., Dinapoli, R., Daube, J., Bartleson, J. et al. (1982) Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol11: 136-141.
32.
Dyck, P., O'Brien, P., Swanson, C., Low, P. and Daube, J. (1985) Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology35: 1173-1176.
33.
Dyck, P.J., Daube, J., O'Brien, P., Pineda, A., Low, P.A., Windebank, A.J. et al. (1986) Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med314: 461-465.
34.
Dyck, P.J., Litchy, W.J., Kratz, K.M., Suarez, G.A., Low, P.A., Pineda, A.A. et al. (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy . Ann Neurol36: 838-845.
35.
Dyck, P.J., Low, P.A., Windebank, A.J., Jaradeh, S.S., Gosselin, S., Bourque, P. et al. (1991) Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med325: 1482-1486.
36.
European Federation of Neurological Societies ( 2006) European Federation of Neurological Societies/ Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society, J Peripher Nerv Syst11: 1-8.
37.
Federico, P., Zochodne, D., Hahn, A., Brown, W. and Feasby, T. (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology55: 1256-1262.
38.
Feldman, E.L., Bromberg, M.B., Albers, J.W. and Pestronk, A. (1991) Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol30: 397-401.
39.
Felts, P.A., Smith, K.J., Gregson, N.A. and Hughes, R.A. (2002) Brain-derived neurotrophic factor in experimental autoimmune neuritis. J Neuroimmunol124: 62-69.
40.
Fialho, D., Chan, Y., Allen, D., Reilly, M. and Hughes, R. (2006) Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry77: 544-547.
41.
Flachenecker, P., Hartung, H.P. and Reiners, K. (1997a) Power spectrum analysis of heart rate variability in Guillain-Barré syndrome. A longitudinal study. Brain120(Pt 10): 1885-1894.
42.
Flachenecker, P., Wermuth, P., Hartung, H.P. and Reiners, K. (1997b) Quantitative assessment of cardiovascular autonomic function in Guillain-Barré syndrome. Ann Neurol42: 171-179.
43.
French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. (1987) Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids, Ann Neurol22: 753-761.
44.
French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. (1992) Plasma exchange in Guillain-Barré syndrome: one-year follow-up, Ann Neurol32: 94-97.
45.
French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. (1997) Appropriate number of plasma exchanges in Guillain-Barré syndrome, Ann Neurol41: 298-306.
46.
Garssen, M., van Koningsveld, R., van Doorn, P., Merkies, I., Scheltens-de Boer, M., van Leusden, J. et al. (2007) Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry78: 1012-1013.
47.
Gladstone, D., Prestrud, A. and Brannagan, T.R. (2005) High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst10: 11-16.
48.
Gold, R., Hartung, H.P. and Toyka, K.V. (2000) Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today6: 88-91.
49.
Gong, Y., Tagawa, Y., Lunn, M.P., Laroy, W., Heffer-Lauc, M., Li, C.Y. et al. (2002) Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain125: 2491-2506.
50.
Good, J., Chehrenama, M., Mayer, R. and Koski, C. (1998) Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology51: 1735-1738.
51.
Goodall, J., Kosmidis, J. and Geddes, A. (1974) Effect of corticosteroids on course of Guillain-Barré syndrome. Lancet1: 524-526.
52.
Goodfellow, J.A., Bowes, T., Sheikh, K., Odaka, M., Halstead, S.K., Humphreys, P.D. et al. (2005) Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci25: 1620-1628.
53.
Gorson, K., Amato, A. and Ropper, A. (2004) Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology63: 715-717.
54.
Gorson, K., Hughes, R., Cros, D., Pollard, J., Vallat, J., Riester, K. et al. (2008) Efficacy of interferon beta-1 a in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Neurology70: A369.
55.
Gorson, K., Natarajan, N., Ropper, A. and Weinstein, R. (2007) Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve35: 66-69.
56.
Govoni, V. and Granieri, E. (2001) Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol14: 605-613.
57.
Guillain-Barré Syndrome Steroid Trial Group, ( 1993) Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome, Lancet341: 586-590.
58.
Guillain-Barré Syndrome Study Group, (1985 ) Plasmapheresis and acute Guillain-Barré syndrome, Neurology35: 1096-1104.
59.
Gürses, N., Uysal, S., Cetinkaya, F., Işlek, I. and Kalayci, A. (1995) Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis27: 241-243.
60.
Haber, P., DeStefano, F., Angulo, F., Iskander, J., Shadomy, S., Weintraub, E. et al. (2004) Guillain- Barré syndrome following influenza vaccination. JAMA292: 2478-2481.
61.
Hadden, R.D., Gregson, N.A., Gold, R., Smith, K.J. and Hughes, R.A. (2002) Accumulation of immunoglobulin across the `blood-nerve barrier' in spinal roots in adoptive transfer experimental autoimmune neuritis . Neuropathol Appl Neurobiol28: 489-497.
62.
Hadden, R.D., Sharrack, B., Bensa, S., Soudain, S.E. and Hughes, R.A. (1999) Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology53: 57-61.
63.
Hafer-Macko, C.E., Sheikh, K.A., Li, C.Y., Ho, T.W., Cornblath, D.R., McKhann, G.M. et al. (1996) Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol39: 625-635.
64.
Hahn, A., Bolton, C., Zochodne, D. and Feasby, T. (1996a) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain119(Pt 4): 1067-1077.
65.
Hahn, A.F., Bolton, C.F., Pillay, N., Chalk, C., Benstead, T., Bril, V. et al. (1996b) Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain119: 1055-1066.
66.
Halstead, S.K., Humphreys, P.D., Goodfellow, J.A., Wagner, E.R., Smith, R.A. and Willison, H.J. (2005) Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol58: 203-210.
67.
Halstead, S.K., O'Hanlon, G.M., Humphreys, P.D., Morrison, D.B., Morgan, B.P., Todd, A.J. et al. (2004) Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain127: 2109-2123.
68.
Halstead, S.K., Zitman, F.M., Humphreys, P.D., Greenshields, K., Verschuuren, J.J., Jacobs, B.C. et al. (2008) Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain.
69.
Harbo, T., Andersen, H. and Jakobsen, J. (2009) Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve.
70.
Harvey, G., Toyka, K., Zielasek, J., Kiefer, R., Simonis, C. and Hartung, H. (1995) Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve18: 388-394.
71.
Hausmanowa-Petrusewicz, I., RowińskaMarcinska, K. and Kopeć, A. (1991) Chronic acquired demyelinating motor neuropathy. Acta Neurol Scand84: 40-45.
72.
Hirst, C., Raasch, S., Llewelyn, G. and Robertson, N. (2006) Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry77: 800-802.
73.
Ho, T.W., Mishu, B., Li, C.Y., Gao, C.Y., Cornblath, D.R., Griffin, J.W. et al. (1995a) Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies . Brain118(Pt 3): 597-605.
74.
Ho, T.W., Mishu, B., Li, C.Y., Gao, C.Y., Cornblath, D.R., Griffin, J.W. et al. (1995b) Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies . Brain118(Pt 3): 597-605.
75.
Hughes, R., Bensa, S., Willison, H., Van den Bergh, P., Comi, G., Illa, I. et al. (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol50: 195-201.
76.
Hughes, R., Donofrio, P., Bril, V., Dalakas, M., Deng, C., Hanna, K. et al. (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol7: 136-144.
77.
Hughes, R.A. and Cornblath, D.R. (2005) Guillain-Barré syndrome. Lancet366: 1653-1666.
78.
Hughes, R.A., Raphael, J.C., Swan, A.V. and van Doorn, P.A. (2006) Intravenous immunoglobulin for Guillain-Barré syndrome . Cochrane Database Syst RevCD002063.
79.
Hughes, R.A. and Rees, J.H. (1997) Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis176(Suppl. 2): S92-98.
80.
Hughes, R.A., Swan, A.V., Raphael, J.C., Annane, D., van Koningsveld, R. and van Doorn, P.A. (2007) Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain130: 2245-2257.
81.
Iijima, M., Koike, H., Hattori, N., Tamakoshi, A., Katsuno, M., Tanaka, F. et al. (2008) Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry79: 1040-1043.
82.
Illa, I., Ortiz, N., Gallard, E., Juarez, C., Grau, J.M. and Dalakas, M.C. (1995) Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol38: 218-224.
83.
Illés, Z., Kondo, T., Newcombe, J., Oka, N., Tabira, T. and Yamamura, T. (2000) Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol164: 4375-4381.
84.
Illés, Z., Shimamura, M., Newcombe, J., Oka, N. and Yamamura, T. (2004) Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int Immunol16: 223-230.
85.
Imbach, P., Barandun, S., d'Apuzzo, V., Baumgartner, C., Hirt, A., Morell, A., Rossi, E., Schöni, M., Vest, M. and Wagner, H. (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet1: 1228-1231.
86.
Jacobs, J.M. and Scadding, J.W. (1990) Morphological changes in IgM paraproteinaemic neuropathy . Acta Neuropathol80: 77-84.
87.
Kaji, R., Oka, N., Tsuji, T., Mezaki, T., Nishio, T., Akiguchi, I. and Kimura, J. (1993) Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol33: 152-158.
88.
Kelly, J.J., Jr., Kyle, R.A., O'Brien, P.C. and Dyck, P.J. (1981) Prevalence of monoclonal protein in peripheral neuropathy. Neurology31: 1480-1483.
89.
Khalili-Shirazi, A., Gregson, N., Gray, I., Rees, J., Winer, J. and Hughes, R. (1999) Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg Psychiatry66: 376-379.
90.
Kieseier, B., Meyer Zu Hörste, G., Lehmann, H., Gold, R. and Hartung, H. (2008) Intravenous immunoglobulins in the treatment of immune neuropathies. Curr Opin Neurol21: 555-562.
91.
Kieseier, B.C. and Hartung, H.P. (2003) Therapeutic strategies in the Guillain-Barré syndrome . Semin Neurol23: 159-168.
92.
Kieseier, B.C., Kiefer, R., Gold, R., Hemmer, B., Willison, H.J. and Hartung, H.P. (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve30: 131-156.
93.
Kieseier, B.C., Krivacic, K., Jung, S., Pischel, H., Toyka, K.V., Ransohoff, R.M. et al. (2000) Sequential expression of chemokines in experimental autoimmune neuritis. J Neuroimmunol110: 121-129.
94.
Kieseier, B.C., Wiendl, H. and Hartung, H.P. (2006) The inflamed peripheral nervous system: update on immune therapies. Curr Opin Neurol19: 433-436.
95.
Köller, H., Kieseier, B.C., Jander, S. and Hartung, H.P. (2005) Chronic inflammatory demyelinating neuropathy. N Engl J Med352: 1343-1356.
96.
Korinthenberg, R., Schessl, J., Kirschner, J. and Mönting, J. (2005) Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics116: 8-14.
97.
Lange, D., Weimer, L., Trojaborg, W., Lovelace, R., Gooch, C. and Rowland, L. (2006) Multifocal motor neuropathy with conduction block: slow but not benign. Arch Neurol63: 1778-1781.
98.
Lasky, T., Terracciano, G., Magder, L., Koski, C., Ballesteros, M., Nash, D. et al. (1998) The Guillain- Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med339: 1797-1802.
99.
Léger, J., Viala, K., Cancalon, F., Maisonobe, T., Gruwez, B., Waegemans, T. et al. (2008) Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry79: 93-96.
100.
Léger, J.M., Chassandre, B., Musset, L., Meininger, V., Bouche, P. and Baumann, N. (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain124: 145-153.
101.
Lehmann, H.C. and Hartung, H.P. (2008) Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies. Brain131: 1168-1170.
102.
Lehmann, H.C., Hartung, H.-P., Hetzel, G.R., Stüve, O. and Kieseier, B.C. (2006) Plasma exchange in neuroimmunological disorders. Part 2 Treatment of neuromuscular disorders. Arch Neurol63: 1066-1071.
103.
Lehmann, H.C., Hoffmann, F.R., Fusshoeller, A., Hetzel, G.R., Hartung, H.P., Schroeter, M. et al. (2008) The therapeutic value of plasma exchange in multifocal motor neuropathy. J Neurol Sci27: 34-9.
104.
Lehmann, H.C., Kohne, A., zu Horste, G.M. and Kieseier, B.C. (2007a) Incidence of Guillain-Barré syndrome in Germany . J Peripher Nerv Syst12: 285.
105.
Lehmann, H.C., Köhne, A., Meyer zu Hörste, G., Dehmel, T., Kiehl, O., Hartung, H.P., Kastenbauer, S. and Kieseier, B.C. (2007b) Role of nitric oxide as mediator of nerve injury in inflammatory neuropathies. J Neuropathol Exp Neurol66: 305-312.
106.
Lehmann, H.C., Lopez, P.H., Zhang, G., Ngyuen, T., Zhang, J., Kieseier, B.C., Mori, S. and Sheikh, K.A. (2007c) Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci27: 27-34.
107.
Levine, T. and Pestronk, A. (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology52: 1701-1704.
108.
Lombardi, R., Erne, B., Lauria, G., Pareyson, D., Borgna, M., Morbin, M. et al. (2005) IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy. Ann Neurol57: 180-187.
109.
Lonigro, A. and Devaux, J.(2009) Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain132: 260-273.
110.
Lopate, G., Pestronk, A. and Al-Lozi, M. (2005) Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone . Arch Neurol62: 249-254.
111.
Lunn, M., Manji, H., Choudhary, P., Hughes, R. and Thomas, P. (1999) Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry66: 677-680.
112.
Lunn, M.P., Crawford, T.O., Hughes, R.A., Griffin, J.W. and Sheikh, K.A. (2002) Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing. Brain125: 904-911.
113.
Lunn, M.P. and Nobile-Orazio, E. (2003) Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst RevCD002827.
114.
Lunn, M.P. and Nobile-Orazio, E. (2006) Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst RevCD002827.
115.
Makowska, A., Pritchard, J., Sanvito, L., Gregson, N., Peakman, M., Hayday, A. et al. (2008) Immune responses to myelin proteins in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry79: 664-671.
116.
Mariette, X., Brouet, J., Chevret, S., Leger, J., Clavelou, P., Pouget, J. et al. (2000) A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry69: 279-280.
117.
McLeod, J., Pollard, J., Macaskill, P., Mohamed, A., Spring, P. and Khurana, V. (1999) Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol46: 910-913.
118.
Mehndiratta, M.M. and Singh, A.C. (2007) Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy. Curr Allergy Asthma Rep7: 274-279.
119.
Mendell, J., Barohn, R., Freimer, M., Kissel, J., King, W., Nagaraja, H. et al. (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology56: 445-449.
120.
Merkies, I.S.J., Bril, V., Dalakas, M.C., Deng, C.Q., Donofrio, P., Hanna, K. et al. (2008) Quality-of-life (QoL) improvements with immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C) in chronic inflammatory demyelinating polyneuropathy (CIDP). Ann Neurol64: S4-S5.
121.
Meyer zu Horste, G., Hartung, H.P. and Kieseier, B.C. (2007) From bench to bedside- experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol3: 198-211.
122.
Midroni, G., de Tilly, L., Gray, B. and Vajsar, J. (1999) MRI of the cauda equina in CIDP: clinical correlations . J Neurol Sci170: 36-44.
123.
Moore, R. and Derry, S. (2006) Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther8: R182.
124.
Muley, S., Kelkar, P. and Parry, G. (2008) Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol65: 1460-1464.
125.
Niermeijer, J.M.F., Eurelings, M., van der Linden, M.W., Lokhorst, H.M., Franssen, H., Fischer, K. et al. (2007) Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology69: 50-59.
126.
Nobile-Orazio, E. (2001) Multifocal motor neuropathy. J Neuroimmunol115: 4-18.
127.
Nobile-Orazio, E. (2004) IgM paraproteinaemic neuropathies. Curr Opin Neurol17: 599-605.
128.
Nobile-Orazio, E. (2008) Evidence for long-term IVIg treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Nat Clin Pract Neurol4: 352-353.
129.
Nobile-Orazio, E., Cappellari, A. and Priori, A. (2005) Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve31: 663-680.
130.
O'Hanlon, G.M., Humphreys, P.D., Goldman, R.S., Halstead, S.K., Bullens, R.W., Plomp, J.J. et al. (2003) Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain126: 2497-2509.
131.
O'Leary, C.P., Veitch, J., Durward, W.F., Thomas, A.M., Rees, J.H. and Willison, H.J. (1996) Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry61: 649-651.
132.
Odaka, M., Tatsumoto, M., Susuki, K., Hirata, K. and Yuki, N. (2005) Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry76: 1115-1120.
133.
Ogawa-Goto, K. and Abe, T. (1998) Gangliosides and glycosphingolipids of peripheral nervous system myelins - a minireview. Neurochem Res23: 305-310.
134.
Ogawa-Goto, K., Funamoto, N., Abe, T. and Nagashima, K. (1990) Different ceramide compositions of gangliosides between human motor and sensory nerves. J Neurochem55: 1486-1493.
135.
Overell, J.R. and Willison, H.J. (2005) Recent developments in Miller Fisher syndrome and related disorders. Curr Opin Neurol18: 562-566.
136.
Pestronk, A., Cornblath, D.R., Ilyas, A., Baba, H., Quarles, R.H., Griffin, J.W. et al. (1988) A treatable multifocal motor neuropathy with antbodies to GM1 ganglioside. Ann Neurol24: 73-78.
137.
Pestronk, A., Florence, J., Miller, T., Choksi, R., Al-Lozi, M. and Levine, T. (2003) Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry74: 485-489.
138.
Piepers, S., Van den Berg-Vos, R., Van der Pol, W., Franssen, H., Wokke, J. and Van den Berg, L. (2007) Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain130: 2004-2010.
139.
Plasma Exchange/Sandoglobobulin Guillain-Barré Syndrom Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome . Lancet349: 225-230.
140.
Prineas, J.W. (1981) Pathology of the Guillain-Barré syndrome. Ann Neurol9(Suppl.): 6-19.
141.
Pritchard, J., Gray, I.A., Idrissova, Z.R., Lecky, B.R., Sutton, I.J., Swan, A.V. et al. (2003) A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology61: 1282-1284.
142.
Ramos-Alvarez, M., Bessudo, L. and Sabin, A.B. (1969) Paralytic syndromes associated with noninflammatory cytoplasmic or nuclear neuronopathy. Acute paralytic disease in Mexican children, neuropathologically distinguishable from Landry-Guillain- Barré syndrome. JAMA207: 1481-1492.
143.
Rees, J.H., Thompson, R.D., Smeeton, N.C. and Hughes, R.A. (1998) Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry64: 74-77.
144.
Reményi, P., Masszi, T., Borbényi, Z., Soós, J., Siklós, L. and Engelhardt, J. (2007) CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol14: e1-2.
145.
Renaud, S., Fuhr, P., Gregor, M., Schweikert, K., Lorenz, D., Daniels, C. et al. (2006) High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology66: 742-744.
146.
Renaud, S., Gregor, M., Fuhr, P., Lorenz, D., Deuschl, G., Gratwohl, A. et al. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve27: 611-615.
147.
Ritz, M., Erne, B., Ferracin, F., Vital, A., Vital, C. and Steck, A. (1999) Anti-MAG IgM penetration into myelinated fibers correlates with the extent of myelin widening. Muscle Nerve22: 1030-1037.
148.
Rojas-García, R., Gallardo, E., de Andrés, I.,de Luna, N., Juarez, C., Sánchez, P. and Illa, I. (2003) Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology61: 1814-1816.
149.
Ropper, A.H. and Gorson, K.C. (1998) Neuropathies associated with paraproteinemia. N Engl J Med338: 1601-1607.
150.
Ruegg, S.J., Fuhr, P. and Steck, A. (2004) Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology63: 2178-2179.
151.
Ruts, L., Rico, R., van Koningsveld, R., Botero, J., Meulstee, J., Gerstenbluth, I., Merkies, I. and van Doorn, P. (2008) Pain accompanies pure motor Guillain-Barré syndrome . J Peripher Nerv Syst13: 305-306.
152.
Ruts, L., van Koningsveld, R., Jacobs, B. and van Doorn, P.(2007) Determination of pain and response to methylprednisolone in Guillain-Barré syndrome. J Neurol254: 1318-1322.
153.
Ryan, M., Grattan-Smith, P., Procopis, P., Morgan, G. and Ouvrier, R. (2000) Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome. Neuromusc Disord10: 398-406.
154.
Sanvito, L., Makowska, A., Mahdi-Rogers, M., Hadden, R., Peakman, M., Gregson, N. et al. (2009) Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry80: 333-338.
155.
Schmidt, B., Toyka, K.V., Kiefer, R., Full, J., Hartung, H.P. and Pollard, J. (1996) Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy . Muscle Nerve19: 474-487.
156.
Sedano, M.J., Calleja, J., Canga, E. and Berciano, J. (1994) Guillain-Barré syndrome in Cantabria, Spain. An epidemiological and clinical study. Acta Neurol Scand89: 287-292.
157.
Sheikh, K.A., Deerinck, T.J., Ellisman, M.H. and Griffin, J.W. (1999) The distribution of ganglioside-like moieties in peripheral nerves. Brain122(Pt 3): 449-460.
158.
Singh, N.K. and Gupta, A. (1996) Do corticosteroids influence the disease course or mortality in Guillain-Barre' syndrome? J Assoc Physicians India44: 22-24.
159.
Slee, M., Selvan, A. and Donaghy, M. (2007) Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology69: 1680-1687.
160.
Specht, S., Claus, D. and Zieschang, M. (2000) Plasmapheresis in multifocal motor neuropathy: a case report. J Neurol Neurosurg Psychiatry68: 533-535.
161.
Susuki, K., Rasband, M.N., Tohyama, K., Koibuchi, K., Okamoto, S., Funakoshi, K. et al. (2007) Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci27: 3956-3967.
162.
Svennerholm, L., Bostrom, K., Fredman, P., Jungbjer, B., Lekman, A., Mansson, J.E. et al. (1994) Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta1214: 115-123.
163.
Svennerholm, L., Bostrom, K., Fredman, P., Jungbjer, B., Mansson, J.E. and Rynmark, B.M. (1992) Membrane lipids of human peripheral nerve and spinal cord. Biochim Biophys Acta1128: 1-7.
164.
Tackenberg, B., Lünemann, J., Steinbrecher, A., Rothenfusser-Korber, E., Sailer, M., Brück, W. et al. (2007) Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology68: 1622-1629.
165.
Taylor, B., Dyck, P., Engelstad, J., Gruener, G. and Grant, I. (2004) Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol63: 129-137.
166.
Taylor, B., Wright, R., Harper, C. and Dyck, P. (2000) Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve23: 900-908.
167.
Terenghi, F., Cappellari, A., Bersano, A., Carpo, M., Barbieri, S. and Nobile-Orazio, E. (2004) How long is IVIg effective in multifocal motor neuropathy? Neurology62: 666-668.
168.
Van Asseldonk, J.T., Franssen, H., Van den Berg-Vos, R.M., Wokke, J.H. and Van den Berg, L.H. (2005) Multifocal motor neuropathy . Lancet Neurol4: 309-319.
169.
Van Asseldonk, J.T.H., Van den Berg, L.H., Kalmijn, S., Van den Berg-Vos, R.M., Polman, C.H., Wokke, J.H.J. et al. (2006) Axon loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry77: 743-747.
170.
Van den Berg, L., Franssen, H., Van Doorn, P. and Wokke, J. (1997) Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies. J Neurol Neurosurg Psychiatry63: 674-677.
171.
van der Meche, F.G. and Schmitz, P.I.(1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. The Dutch Guillain-Barré Study Group . N Engl J Med326: 1123-1129.
172.
van Doorn, P., Brand, A., Strengers, P., Meulstee, J. and Vermeulen, M. (1990) High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology40: 209-212.
173.
van Doorn, P.A., Ruts, L. and Jacobs, B.C. (2008) Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol7: 939-950.
174.
van Koningsveld, R., Schmitz, P.I., Meche, F.G., Visser, L.H., Meulstee, J. and van Doorn, P.A. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet363: 192-196.
175.
van Koningsveld, R., Van Doorn, P., Schmitz, P., Ang, C. and Van der Meche, F. (2000) Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology54: 620-625.
176.
Van Schaik, I.N., Winer, J.B., De Haan, R. and Vermeulen, M. (2002) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst RevCD001797.
177.
Vermeulen, M. (2008) Intravenous immunoglobulin: a first-line treatment in CIDP?. Lancet Neurol7: 115-116.
178.
Vermeulen, M., van Doorn, P., Brand, A., Strengers, P., Jennekens, F. and Busch, H. (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry56: 36-39.
179.
Vital, A. (2001) Paraproteinemic neuropathies. Brain Pathol11: 399-407.
180.
Wanschitz, J., Maier, H., Lassmann, H., Budka, H. and Berger, T. (2003) Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome. Brain126: 2034-2042.
181.
Willison, H.J. (2002) Anti-glycolipid antibodies in the diagnosis of autoimmune neuropathies. Rev Neurol ( Paris) 158: S16-20.
182.
Willison, H.J. (2005) The immunobiology of Guillain- Barré syndromes . J Peripher Nerv Syst10: 94-112.
183.
Willison, H.J., Townson, K., Veitch, J., Boffey, J., Isaacs, N., Andersen, S.M. et al. (2004) Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. Brain127: 680-691.
184.
Willison, H.J. and Yuki, N. (2002) Peripheral neuropathies and anti-glycolipid antibodies . Brain125: 2591-2625.
185.
Winer, J., Hughes, S., Cooper, J., Ben-Smith, A. and Savage, C. (2002) Gamma delta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol249: 616-621.
186.
Yan, W.X., Taylor, J., Andrias-Kauba, S. and Pollard, J.D. (2000) Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol47: 765-775.
187.
Yan, W.X., Archelos, J.J., Hartung, H.-P. and Pollard, J.D. (2000) PO protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol50: 286-292.
188.
Yuki, N. (1997) Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome. J Infect Dis176: S150-153.
189.
Yuki, N. (2005) Carbohydrate mimicry: a new paradigm of autoimmune diseases. Curr Opin Immunol17: 577-582.
190.
Yuki, N. and Odaka, M. (2005) Ganglioside mimicry as a cause of Guillain-Barré syndrome. Curr Opin Neurol18: 557-561.
191.
Yuki, N., Tagawa, Y. and Hirata, K. (1998) Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barré syndrome. Neurology51: 875-877.
192.
Yuki, N., Taki, T., Inagaki, F., Kasama, T., Takahashi, M., Saito, K. et al. (1993) A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med178: 1771-1775.
193.
Yuki, N., Taki, T., Takahashi, M., Saito, K., Yoshino, H., Tai, T. et al. (1994) Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol36: 791-793.
194.
Yuki, N., Yoshino, H., Sato, S. and Miyatake, T. (1990) Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology40: 1900-1902.
195.
Zhang, G., Lopez, P.H., Li, C.Y., Mehta, N.R., Griffin, J.W., Schnaar, R.L. et al. (2004) Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain127: 1085-1100.
